Gene

Targeted therapy

Cell biology

Biology

Proteolysis

Ubiquitin ligase

Cancer research

Biochemistry

Ubiquitin

Computational biology

Genetics

Enzyme

Cancer therapy

Proteasome

Cancer

Protein degradation

Molecular Cancer

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system. PROTAC has emerged as a promising approach for targeted therapy in various diseases, particularly in cancers. In this review, we introduce the principle and development of PROTAC technology, as well as the advantages of PROTACs over traditional anti-cancer therapies. Moreover, we summarize the application of PROTACs in targeting critical oncoproteins, provide the guidelines for the molecular design of PROTACs and discuss the challenges in the targeted degradation by PROTACs.

Proteolysis-targeting chimeras (PROTACs) in cancer therapy